Table 1

Characteristics of the included prospective cohort studies

StudyDesign and locationStudy periodsNumber of participantsMean ageMaleAdiponectin measurementAF outcome assessmentFollow-up durationAF casesAdjusted factorsQuality score
YearYears%Yearsn (%)
2012 Framingham Offspring Study [13]PC, U.S.A.1999–200924876146Total, ELISAECG or Holter7.6206 (8.3)Age, sex, BMI, SBP, treatment of hypertension, PR interval, clinically significant cardiac murmur, HF, and CRP9
2014 Busselton Health Study [14]PC, Australia1995–201042675247Total, ELISAHospitalization of AF15.0343 (8.0)Age, sex, height, hypertension treatment and BMI8
2015 Cardiovascular Health Study [16]PC, U.S.A.1992–2009319074 (>65)36Total and HMW, ELISAECG or hospitalization of AF11.4886 (27.8)Age, sex, race, educational status, height, weight, SBP, treatment of hypertension, smoking, alcohol, self-reported health status, estimated GFR, NT-proBNP, subclinical CVD, DM, LDL-C, HDL-C, TG and hsCRP9
2015 Health ABC Study [15]PC, U.S.A.1992–2013276873 (70–79)48Total, RIAECG or hospitalization of AF10.9721 (26.0)Race, age, sex, BMI, smoking, alcohol, statin treatment, hypertension, DM, CAD, HF and study site9
2016 Women’s Health Initiative Study [17]PC, U.S.A.1993–2014493766 (50–79)0Total, Multiplex assayECG or hospitalization of AF11.1892 (18.1)Age, race, education, hypertension, DM, hyperlipidemia, CAD, HF, PAD, smoking, history of cancer and BMI9
2017 Bruneck Study [18]PC, Austria1990–201090959 (40–79)50.7Total, ELISAECG or Holter or hospitalization of AF20.0117 (12.9)Age and sex8
  • Abbreviations: BMI, body mass index; CRP, C-reactive protein; GFR, glomerular filtrating rate; HDL-C, high-density lipoprotein cholesterol; hsCRP, highly sensitive C-reactive protein; LDL-C, low-density lipoprotein cholesterol; NT-proBNP, N-terminal pro-B type natriuretic peptide; PAD, peripheral artery disease; PC, prospective cohort; RIA, radioimmunoassay; SBP, systolic blood pressure; TG, triglyceride.